시력 관리 시장 : 시장 점유율 분석, 산업 동향 및 통계 데이터, 성장 예측(2026-2031년)

According to Mordor Intelligence, the vision care market size was valued at USD 69.70 billion in 2025 and is estimated to grow from USD 75.14 billion in 2026 to reach USD 109.38 billion by 2031, at a CAGR of 7.80% during the forecast period (2026-2031).

This report is Segmented by Product Type (Spectacle Lenses, Contact Lenses, Intraocular Lenses, Ocular Health Products, Vision Correction Devices), Application (Corrective, Therapeutic, Preventive, Cosmetic), Age Group (Pediatric, Adult, Geriatric), Distribution Channel (Optical Retail, Hospitals, E-Commerce, Pharmacies), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Vision Care Market Trends and Insights

Rising Refractive Errors and Myopia Burden

The vision care market is experiencing growth due to the increasing prevalence of refractive errors, particularly myopia, among children and adolescents. A 2025 review highlighted that global myopia prevalence in this group reached 35.81% in 2023 and is projected to rise to 39.80% by 2050, affecting nearly 740 million individuals. This trend is driving the market beyond single-vision correction toward products designed to slow myopia progression, enhancing value per patient. The FDA's approval of Essilor Stellest in 2025, the first spectacle lens in the U.S. to slow pediatric myopia progression, has expanded the addressable market. Additionally, China's focus on school-level myopia screenings continues to drive demand, particularly in East Asia, where prevalence rates are already high.

Aging-Driven Demand for Presbyopia and Cataract Care

The aging population is fueling demand for presbyopia correction, cataract surgeries, and improved postoperative vision, contributing to the vision care market's growth. Cataracts remain the leading cause of global blindness, with over 20 million surgeries performed annually, including 4.3 million in Europe and 3.8 million in the U.S. The market is seeing a shift toward premium intraocular lenses, which reduce spectacle dependence and generate out-of-pocket payments even in reimbursed systems. Alcon's launch of Clareon PanOptix Pro in 2025 and Bausch + Lomb's reported premium IOL growth of over 20% in Q4 2025 highlight the increasing preference for advanced visual outcomes. With global blindness and visual impairments projected to rise from 338.3 million in 2020 to 535 million by 2050, the aging trend will continue to support market expansion

Premium-Product Affordability and Reimbursement Gaps

The vision care market faces a significant challenge as clinical needs far exceed the affordability of premium corrective or therapeutic services for many patients. The World Health Organization's SPECS 2030 framework aims to address this gap by increasing coverage for refractive error services by 2030. Annual productivity losses from uncorrected myopia are estimated at USD 244 billion globally, with many in low-income regions still lacking basic eyeglasses. This economic barrier impacts the adoption of fast-growing product segments like myopia-control lenses and premium surgical implants, which often rely on out-of-pocket spending. Without expanded reimbursements or affordable alternatives, affordability will continue to limit growth in high-potential regions.

Other drivers and restraints analyzed in the detailed report include:

1. Digital-Eye-Strain Demand for Premium Lenses and Coatings
2. Omnichannel Optical Retail and E-Commerce Expansion
3. Counterfeit Products and Online Compliance Friction

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Spectacle lenses accounted for 52.45% of the vision care market in 2025, maintaining their position as the leading product type due to their widespread prescription and ease of adoption across patient groups. This reflects the foundational role of spectacles in addressing refractive errors in both developed and developing regions. Premium designs, advanced coatings, and myopia-control features are driving revenue growth, even as unit sales grow at a slower pace.

Contact lenses are the fastest-growing segment, with an 8.20% CAGR projected through 2031. Growth is driven by premium daily disposables, improved comfort, and their increasing role in myopia management, narrowing the value gap with premium spectacles. Intraocular lenses are also gaining traction due to rising cataract surgeries and a shift toward trifocal and extended-depth-of-focus designs, enhancing postoperative visual range.

Corrective vision care held 44.6% of the market share in 2025, reflecting its role as the core revenue driver for optical dispensing and routine prescription updates. Most patient journeys in vision care begin with refraction and standard correction, ensuring the segment's continued relevance. However, providers are broadening the scope of visits to include recurring therapy, diagnostics, and follow-up care, moving beyond single corrective sales.

Therapeutic and disease management is the fastest-growing segment, with a 9.10% CAGR projected through 2031. Bausch + Lomb's dry eye portfolio exceeded USD 1.1 billion in FY2025 revenue, with MIEBO contributing USD 316 million, highlighting the growing therapeutic market. Preventive and protective vision care is expanding as awareness of UV exposure, dry eye, and workplace strain increases. Cosmetic and lifestyle vision care remains a smaller niche, influenced more by fashion trends, safety compliance, and urban spending than disease prevalence.

Geography Analysis

In 2025, North America accounted for 44.67% of the global vision care market, driven by high per-capita spending, extensive private coverage, and strong innovation cycles. The U.S. leads regional demand due to a significant myopic population and rapid commercialization of new products. The FDA's approval of Essilor Stellest in September 2025 and the expanded age criteria for EVO ICL treatments in February 2026 have broadened access to premium care. While Canada and Mexico add depth, the U.S. remains the primary driver of pricing power. Cost inflation poses a challenge, with Alcon projecting a net tariff impact of USD 125 million to USD 175 million in its 2026 guidance.

Europe remains a mature vision care market, supported by aging populations, established clinical networks, and steady adoption of premium surgical products. Growth varies across the region due to differences in reimbursement policies and consumer spending between Western and Eastern Europe. Germany's optical market, for example, reported only 1% to 2% revenue growth in early 2026, constrained by cautious consumer spending. EssilorLuxottica's acquisition of Optegra highlights the growing integration of ophthalmology services with optical dispensing in the region.

Asia-Pacific is projected to achieve the fastest growth in the vision care market, with a 10.15% CAGR through 2031. The region benefits from high demand density, with myopia prevalence reaching 80% to 90% among school-leavers in parts of East Asia, supported by systematic public screening programs. East Asia leans toward high prevalence and premium product adoption, while China, Japan, India, and Southeast Asia offer growth potential due to uneven access. South America and the Middle East and Africa remain smaller contributors, with progress tied to urbanization and improved access rather than premium product penetration.

1. Alcon
2. Bausch + Lomb Corporation
3. CooperVision Inc.
4. EssilorLuxottica
5. Fielmann Group
6. HOYA
7. JINS
8. Johnson & Johnson
9. Menicon
10. Nidek
11. Rayner
12. Rodenstock
13. Safilo Group S.p.A.
14. SEED Co. Ltd.
15. Shamir Optical Industry
16. STAAR Surgical
17. Topcon
18. Visioneering Technologies
19. Warby Parker
20. ZEISS Vision Care / Carl Zeiss Meditec

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Refractive Errors and Myopia Burden
  • 4.2.2 Aging-Driven Demand for Presbyopia and Cataract Care
  • 4.2.3 Digital-Eye-Strain Demand for Premium Lenses and Coatings
  • 4.2.4 Omnichannel Optical Retail and E-Commerce Expansion
  • 4.2.5 FDA-Authorized Pediatric Myopia-Control Spectacles
  • 4.2.6 Approved Low-Dose Atropine Broadens Pediatric Myopia Care
• 4.3 Market Restraints
  • 4.3.1 Premium-Product Affordability and Reimbursement Gaps
  • 4.3.2 Counterfeit Products and Online Compliance Friction
  • 4.3.3 Tariff-Driven Cost Inflation in Optical Inputs
  • 4.3.4 Quality-System Recalls and Single-Source Component Risk
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Spectacle Lenses
  • 5.1.2 Contact Lenses
  • 5.1.3 Intraocular Lenses
  • 5.1.4 Ocular Health Products
  • 5.1.5 Vision Correction Systems and Devices
• 5.2 By Application
  • 5.2.1 Corrective Vision Care
  • 5.2.2 Therapeutic and Disease Management
  • 5.2.3 Preventive and Protective Vision Care
  • 5.2.4 Cosmetic and Lifestyle Vision Care
• 5.3 By Age Group
  • 5.3.1 Pediatric
  • 5.3.2 Adult
  • 5.3.3 Geriatric
• 5.4 By Distribution Channel
  • 5.4.1 Optical Retail Stores and Chains
  • 5.4.2 Hospitals and Ophthalmology Clinics
  • 5.4.3 E-Commerce Platforms
  • 5.4.4 Pharmacies and Drugstores
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Alcon Inc.
  • 6.3.2 Bausch + Lomb Corporation
  • 6.3.3 CooperVision Inc.
  • 6.3.4 EssilorLuxottica
  • 6.3.5 Fielmann Group
  • 6.3.6 HOYA Corporation
  • 6.3.7 JINS
  • 6.3.8 Johnson & Johnson Vision
  • 6.3.9 Menicon Co., Ltd.
  • 6.3.10 Nidek Co., Ltd.
  • 6.3.11 Rayner
  • 6.3.12 Rodenstock GmbH
  • 6.3.13 Safilo Group S.p.A.
  • 6.3.14 SEED Co. Ltd.
  • 6.3.15 Shamir Optical Industry
  • 6.3.16 STAAR Surgical
  • 6.3.17 Topcon Corporation
  • 6.3.18 Visioneering Technologies
  • 6.3.19 Warby Parker
  • 6.3.20 ZEISS Vision Care / Carl Zeiss Meditec

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment